Skip to main content
Blizard Institute - Faculty of Medicine and Dentistry

Professor Chloe Orkin, MBBCH, MSc Infectious Disease LSTHM FRCP


Professor of HIV Medicine

Centre: Centre for Immunobiology

Telephone: 0203 594 6772
Twitter: @profchloeorkin


Professor Orkin is the Lead for HIV research at Barts Health NHS Trust and directs the SHARE Collaborative.

Following a successful 16-year clinical career at Barts Health NHS Trust, Chloe was appointed Professor of HIV Medicine at Queen Mary University of London in 2019. She leads an internationally renowned therapeutic trials unit that has made major contributions to drug development and the licensing of around 20 new therapies. Chloe is global lead author for the FLAIR study which evaluated the first-ever long-acting injectable HIV therapy and was published in the NEJM. Chloe is lead investigator for several other pivotal therapeutic trials and local principal investigator for a COVID-19 monoclonal antibody study. Her research also focuses on ways of including and engaging women, pregnant women and racially minoritised people in clinical trials. Chloe led research and blood-borne virus testing campaigns (Going Viral and Test Me East) in emergency departments which have changed practice.

As President of the Medical Women’s Federation, and a visible LGBTQ+ role-model, Chloe advocates at national fora such as the Department of Health and Social Care Gender Pay-gap Implementation Panel and the General Medical Council Equality forum. As Chair of the British HIV Association (2016-19) she challenged discriminatory legislature and is considered a global medical leader for the U=U campaign.

Chloe is the Academic Lead for Equality, Diversity and Inclusion at Queen Mary's School of Medicine and Dentistry and past Athena SWAN Chair. She is committed to driving culture change and embedding citizenship.


Research Interests:

Professor Orkin's research interests lie in clinical trials in the development of novel anti-retroviral therapy and novel anti-retroviral strategies; and blood-borne virus testing.


Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavi-renz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immuno-deficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 Feb 1;68(4):535-544.

Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised,non-inferiority trial. Lancet HIV. 2017 Oct 5. pii: S2352-3018(17)30179-0. doi:10.1016/S2352-3018(17)30179-0.

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 Mar 1. pii: S2352-3018(17)30031-0. doi: 10.1016/S2352-3018(17)30031-0.

Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K,Anderson J, Tong CY, Lattimore S. In-corporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign. HIV Med. 2016 Mar;17(3):222-30. doi: 10.1111/hiv.12364. PubMed PMID: 26919291.

Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019 Jul 12. pii: S2352-3018(19)30149-3. doi: 10.1016/S2352-3018(19)30149-3. [Epub ahead of print] PubMed PMID: 31307948.